Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10927258 | PROVEPHARM SAS | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(14 years from now) | |
US11499050 | PROVEPHARM SAS | NA |
Dec, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 8, 2027 |
NCE-1 date: 2026-07-08
Market Authorisation Date: 08 July, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
3
United States
2
India
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic